Preferred Name | Darunavir | |
Synonyms |
|
|
Definitions |
A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C65364 |
|
CAS_Registry |
206361-99-1 |
|
CHEBI_ID |
CHEBI:367163 |
|
Chemical_Formula |
C27H37N3O7S |
|
code |
C65364 |
|
Contributing_Source |
FDA |
|
definition |
A human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor, with activity against HIV. Upon oral administration, darunavir selectively targets and binds to the active site of HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease. This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected cells. This inhibition leads to the production of immature, non-infectious viral proteins that are unable to form mature virions, and prevents HIV replication. |
|
FDA_UNII_Code |
YO603Y8113 |
|
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 |
|
label |
Darunavir |
|
Legacy Concept Name |
Darunavir |
|
Preferred_Name |
Darunavir |
|
prefixIRI |
NCIT:C65364 |
|
prefLabel |
Darunavir |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C1435444 |
|
subClassOf |